NCI 标准风险 B 淋巴细胞白血病巩固治疗结束时微小残留病的预后影响：来自儿童肿瘤学组的报告。
Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group.
机构信息
Division of Pediatric Hematology/Oncology, Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas, USA.
Department of Biostatistics, Colleges of Medicine, Public Health and Health Professions, University of Florida, Gainesville, Florida, USA.
出版信息
Pediatr Blood Cancer. 2021 Apr;68(4):e28929. doi: 10.1002/pbc.28929. Epub 2021 Feb 9.
Abstract
The 5-year disease-free survival (DFS) of National Cancer Institute (NCI) high-risk (HR) B-lymphoblastic leukemia (B-ALL) patients with end of induction (EOI) minimal residual disease (MRD) ≥0.1% and end of consolidation (EOC) MRD ≥0.01% is 39 ± 7%, warranting consideration of hematopoietic stem cell transplant (HSCT). However, the impact of EOC MRD in NCI standard-risk (SR) B-ALL patients using COG regimens is unknown. We found that SR patients with MRD ≥0.01% at both EOI and EOC have a 4-year DFS/overall survival (OS) of 72.9 ± 19.0%/91.7 ± 10.8% versus 90.7 ± 2.9%/95.5 ± 2.0% (p = .0019/.25) for those with EOI MRD ≥0.01% and EOC MRD <0.01%. These data suggest that routine use of HSCT may not be warranted in EOC MRD ≥0.01% SR patients.
摘要
美国国家癌症研究所（NCI）高危（HR）B 淋巴细胞白血病（B-ALL）患者在诱导结束（EOI）时微小残留病（MRD）≥0.1%和巩固结束（EOC）时 MRD≥0.01%的 5 年无病生存率（DFS）为 39±7%，需要考虑造血干细胞移植（HSCT）。然而，COG 方案治疗 NCI 标准风险（SR）B-ALL 患者中 EOC MRD 的影响尚不清楚。我们发现，EOI 和 EOC 时 MRD≥0.01%的 SR 患者的 4 年 DFS/总生存率（OS）分别为 72.9±19.0%/91.7±10.8%和 90.7±2.9%/95.5±2.0%（p=0.0019/0.25），而 EOI MRD≥0.01%和 EOC MRD<0.01%的患者。这些数据表明，对于 EOC MRD≥0.01%的 SR 患者，常规使用 HSCT 可能没有必要。
相似文献
1
Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group.NCI 标准风险 B 淋巴细胞白血病巩固治疗结束时微小残留病的预后影响：来自儿童肿瘤学组的报告。
Pediatr Blood Cancer. 2021 Apr;68(4):e28929. doi: 10.1002/pbc.28929. Epub 2021 Feb 9.
2
[Minimal residual disease in adults with Philadelphia chromosome negative acute lymphoblastic leukemia in high-risk].[费城染色体阴性成人高危急性淋巴细胞白血病的微小残留病]
Zhonghua Xue Ye Xue Za Zhi. 2019 Jul 14;40(7):554-560. doi: 10.3760/cma.j.issn.0253-2727.2019.07.004.
3
Measurable Residual Disease Assessment and Allogeneic Transplantation as Consolidation Therapy in Adult Acute Lymphoblastic Leukemia in Colombia.哥伦比亚成人急性淋巴细胞白血病巩固治疗中的可测量残留病评估和异基因移植。
Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):e365-e372. doi: 10.1016/j.clml.2020.11.010. Epub 2020 Nov 14.
4
Prospective evaluation of minimal residual disease monitoring to predict prognosis of adult patients with Ph-negative acute lymphoblastic leukemia.前瞻性评估微小残留病监测对预测 Ph 阴性成人急性淋巴细胞白血病患者预后的价值。
Eur J Haematol. 2019 Sep;103(3):164-171. doi: 10.1111/ejh.13268. Epub 2019 Jul 5.
5
Outcomes of Adults with Acute Lymphoblastic Leukemia After Autologous Hematopoietic Stem Cell Transplantation and the Significance of Pretransplantation Minimal Residual Disease: Analysis from a Single Center of China.中国单中心成人急性淋巴细胞白血病自体造血干细胞移植后的结局及移植前微小残留病的意义分析
Chin Med J (Engl). 2015 Aug 5;128(15):2065-71. doi: 10.4103/0366-6999.161365.
6
Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.移植前微小残留病灶阴性预测 CAR-T 治疗后行单倍体相合造血干细胞移植治疗复发/难治性急性淋巴细胞白血病的良好结局：一项多中心回顾性研究。
J Hematol Oncol. 2020 May 4;13(1):42. doi: 10.1186/s13045-020-00873-7.
7
Clinical Implications of Minimal Residual Disease Detection in Infants With -Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol.《基于 Interfant-06 方案治疗伴有 - 重现性急性淋巴细胞白血病婴儿患者中微小残留病灶检测的临床意义》。
J Clin Oncol. 2021 Feb 20;39(6):652-662. doi: 10.1200/JCO.20.02333. Epub 2021 Jan 6.
8
Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.根据强化治疗后流式细胞术评估的早期细胞形态学反应和微小残留病对青少年和成人高危费城染色体阴性急性淋巴细胞白血病的治疗：PETHEMA ALL-AR-03 试验的最终结果。
J Clin Oncol. 2014 May 20;32(15):1595-604. doi: 10.1200/JCO.2013.52.2425. Epub 2014 Apr 21.
9
Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.适应性反应治疗的不同亚型急性淋巴细胞白血病患儿微小残留病的临床影响
Leukemia. 2017 Feb;31(2):333-339. doi: 10.1038/leu.2016.234. Epub 2016 Aug 18.
10
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.儿童急性淋巴细胞白血病微小残留病的临床意义及其与其他预后因素的关系：一项儿童肿瘤研究组的研究
Blood. 2008 Jun 15;111(12):5477-85. doi: 10.1182/blood-2008-01-132837. Epub 2008 Apr 3.
引用本文的文献
1
Blinatumomab as postremission therapy replaces consolidation and substantial parts of maintenance chemotherapy and results in stable MRD negativity in children with newly diagnosed B-lineage ALL.Blinatumomab 作为缓解后治疗方案，替代了巩固治疗和大部分维持化疗，使新诊断为 B 细胞急性淋巴细胞白血病的儿童获得稳定的微小残留病灶阴性。
J Immunother Cancer. 2024 Jun 6;12(6):e008213. doi: 10.1136/jitc-2023-008213.
2
Securing access to a comprehensive diagnostic panel for children with suspected acute lymphoblastic leukemia: Results from the Mexico in Alliance with St. Jude "Bridge Project".确保疑似急性淋巴细胞白血病儿童能够获得全面的诊断检测：墨西哥与圣裘德儿童研究医院“桥梁项目”的成果
Front Oncol. 2024 Jan 15;13:1286278. doi: 10.3389/fonc.2023.1286278. eCollection 2023.
3
Acute lymphoblastic leukemia in young adults: which up-front treatment?成人急性淋巴细胞白血病：哪种一线治疗？
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):573-580. doi: 10.1182/hematology.2023000510.
4
Extracellular vesicle small RNA cargo discriminates non-cancer donors from pediatric B-lymphoblastic leukemia patients.细胞外囊泡小RNA货物可区分非癌症捐赠者与小儿B淋巴细胞白血病患者。
Front Oncol. 2023 Nov 13;13:1272883. doi: 10.3389/fonc.2023.1272883. eCollection 2023.
5
Acute Myeloid Leukemia Stem Cells in Minimal/Measurable Residual Disease Detection.微小/可测量残留病检测中的急性髓系白血病干细胞
Cancers (Basel). 2023 May 22;15(10):2866. doi: 10.3390/cancers15102866.
6
How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL.我如何利用 CD19 CAR T 细胞治疗成功或失败的风险因素来指导儿童和青少年 B 细胞 ALL 患者的管理。
Blood. 2023 Mar 16;141(11):1251-1264. doi: 10.1182/blood.2022016937.
7
Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia.Blinatumomab 和 inotuzumab 免疫疗法在复发或难治性 B 急性淋巴细胞白血病患儿中的临床应用。
Pediatr Blood Cancer. 2021 Jan;68(1):e28718. doi: 10.1002/pbc.28718. Epub 2020 Oct 24.
本文引用的文献
1
Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000.流式细胞术检测血液微小残留病可预测 AIEOP-BFM-ALL 2000 研究中儿童 B 细胞前体急性淋巴细胞白血病的复发风险。
Pediatr Blood Cancer. 2019 May;66(5):e27590. doi: 10.1002/pbc.27590. Epub 2018 Dec 18.
2
Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG.在巩固/延迟强化治疗期间用环磷酰胺/依托泊苷替代环磷酰胺/阿糖胞苷/巯嘌呤并不能改善儿童 B 细胞急性淋巴细胞白血病的预后：COG 的报告。
Haematologica. 2019 May;104(5):986-992. doi: 10.3324/haematol.2018.204545. Epub 2018 Dec 13.
3
Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001.细化儿童 B 急性淋巴细胞白血病的危险度分类：DFCI ALL 联盟方案 05-001 的结果。
Blood Adv. 2018 Jun 26;2(12):1449-1458. doi: 10.1182/bloodadvances.2018016584.
4
Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131.强化诱导治疗联合克拉屈滨治疗新诊断高危 B 淋巴细胞白血病极高危层患者的相关毒性：来自儿童肿瘤协作组 AALL1131 研究的报告。
Cancer. 2018 Mar 15;124(6):1150-1159. doi: 10.1002/cncr.31099. Epub 2017 Dec 19.
5
Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia.基因型特异性微小残留病解读可改善儿童急性淋巴细胞白血病的分层。
J Clin Oncol. 2018 Jan 1;36(1):34-43. doi: 10.1200/JCO.2017.74.0449. Epub 2017 Nov 13.
6
Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia.儿童急性淋巴细胞白血病的微小残留病指导治疗
Blood. 2017 Apr 6;129(14):1913-1918. doi: 10.1182/blood-2016-12-725804. Epub 2017 Feb 6.
7
Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232.高危B淋巴细胞白血病微小残留病的预后意义：儿童肿瘤协作组AALL0232研究报告
Blood. 2015 Aug 20;126(8):964-71. doi: 10.1182/blood-2015-03-633685. Epub 2015 Jun 29.
8
Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.儿童急性淋巴细胞白血病基于风险治疗背景下序贯微小残留病测量的临床效用：一项前瞻性研究
Lancet Oncol. 2015 Apr;16(4):465-74. doi: 10.1016/S1470-2045(15)70082-3. Epub 2015 Mar 20.
9
Postinduction minimal residual disease monitoring by polymerase chain reaction in children with acute lymphoblastic leukemia.诱导后通过聚合酶链反应对儿童急性淋巴细胞白血病进行微小残留病监测。
J Clin Oncol. 2014 Nov 1;32(31):3553-8. doi: 10.1200/JCO.2014.56.0698. Epub 2014 Oct 6.
10
Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.强化缓解后治疗对临床标准风险和中危急性淋巴细胞白血病儿童和青少年微小残留病定义的高危亚组的影响：一项随机对照试验。(UKALL 2003)
Lancet Oncol. 2014 Jul;15(8):809-18. doi: 10.1016/S1470-2045(14)70243-8. Epub 2014 Jun 9.
Zotero 插件